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Abstract
Background: Burkitt lymphoma is a high-grade B cell lymphoma which accounts for less than 1% of all adult cases
of non-Hodgkin lymphoma. Rare instances of Burkitt lymphoma developing secondary to prior irradiation have
been described in the literature.
Case presentation: We report a case of a 90-year-old white woman with a recent history of irradiation for Hodgkin
lymphoma, who presented with primary Burkitt lymphoma of the supraglottic larynx. She underwent emergency
awake tracheostomy with biopsy. A histopathological examination confirmed non-Hodgkin, B cell lymphoma of
Burkitt type. Given her age and poor functional status, she underwent treatment with palliative radiotherapy.
Conclusions: A literature review was performed to clarify the clinical characteristics of radiation-induced Burkitt
lymphoma in the head and neck, as well as its diagnosis and management. The present case represents the second
case of radiation-induced Burkitt lymphoma in the head and neck in the reported literature, and the first in the
supraglottic larynx. It highlights the need to maintain a broad differential in the assessment of malignancies of the
larynx, particularly in patients with a prior history of radiation treatment.
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Background
Burkitt lymphoma is a high-grade B cell lymphoma that
was first described by Denis Burkitt in the mid-twentieth
century as an aggressive malignancy of the mandible in
African children [1]. The World Health Organization
(WHO) classifies Burkitt lymphoma as endemic, sporadic,
or immunodeficiency-associated, based on underlying
mechanisms of cancer formation. Endemic Burkitt lymph-
oma is that which occurs in African children, and is al-
most always associated with Epstein–Barr virus (EBV)
infection. Sporadic Burkitt lymphoma refers to cases oc-
curring worldwide with no specific geographic distribu-
tion, and accounts for 1 to 2% of adult lymphoma cases in
the USA and Western Europe [2–4]. Tumor cells are
EBV-positive in only 15 to 30% of cases of sporadic Burkitt
lymphoma occurring in the USA [5]. Sporadic Burkitt
lymphoma primarily involves lymph nodes in the abdo-
men, although occasionally occurs extranodally in the
ovaries and kidneys and less frequently presents in the
head and neck as cervical adenopathy. Extranodal head
and neck presentations account for less than 10% of all
cases of sporadic Burkitt lymphoma [6]. Rarely, Burkitt
lymphoma develops secondary to prior irradiation, with
only a few previous cases having been reported in the lit-
erature [7].
We present the case of a 90-year-old woman who was
diagnosed with Burkitt lymphoma of the supraglottic
larynx following radiation for a previous Hodgkin
lymphoma. This is a rare extranodal head and neck
presentation of Burkitt lymphoma, particularly in light
of the patient’s advanced age and her previous radiation
treatment for Hodgkin lymphoma.
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Case presentation
A 90-year-old white woman presented with a large neck
mass and a 6-week history of increasing dysphonia,
stridor, and left-sided otalgia. On examination, there was
a firm 2×3 cm left-sided level III neck mass with no
overlying skin changes. Flexible fiberoptic nasolaryngo-
scopy revealed a large exophytic mass with complete
airway obstruction. A computed tomography (CT)
scan revealed the mass to measure approximately
3.3×3.7×3.1 cm. It was shown to involve her left
supraglottic larynx and extend down to at least the
level of her glottis (Fig. 1).
Eight years earlier, she was diagnosed as having
primary Hodgkin lymphoma in a left cervical node.
Pathology of the node revealed large atypical cells,
Reed–Sternberg cells, and a fine reticular sclerosis pat-
tern. Immunophenotyping performed on a paraffin block
demonstrated positive staining of the large atypical cells
with cluster of differentiation (CD) 15 and CD30. The
stains were negative for leukocyte common antigen
(LCA), CD20, EBV-encoded small ribonucleic acid
(RNA) (EBER). She was classified as Stage 1A classical
Hodgkin lymphoma, mixed cellularity type, which was a
rare diagnosis at age 82. Due to her localized disease,
Fig. 1 Initial computed tomography scan of the patient’s neck showing left neck mass involving the left supraglottic larynx and extending to the
glottis and paraglottic space. The mass extended out through the thyrohyoid membrane and involved the left strap muscle
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she was treated with definitive radiotherapy at a dose of
3500 cGy in 20 fractions delivered over 4 weeks.
Her past medical history was otherwise significant for
a left hip fracture and surgical repair 1 year earlier, as
well as mild cognitive decline, with difficulties in
sequencing, planning, memory, attention, and insight.
Due to her cognitive status, she was reliant on family
members for many of her daily activities.
Following presentation, she underwent an emergency
awake tracheostomy with laryngoscopy and biopsy of the
supraglottic tumor. Microscopic examination revealed
infiltrating sheets of poorly differentiated lymphoid cells
with round nuclei containing several small nucleoli and
dispersed chromatin and a small amount of amphophilic
cytoplasm (Fig. 2). A high mitotic rate and a “starry sky”
appearance, due to numerous tingible body macro-
phages, were noted. An extensive immunohistochemical
panel was performed and the tumor cells were immuno-
reactive for CD20, BCL6, PAX 5, c-myc, and EBER
(Fig. 2). Ki-67, a proliferation index marker, highlighted
almost 100% of cells (Fig. 2). BCL2 was negative. Fluor-
escence in situ hybridization was performed and demon-
strated the confirmatory myc rearrangement. The final
histopathological diagnosis was a non-Hodgkin, B cell
lymphoma of Burkitt type. This was distinct from her
previous diagnosis of Hodgkin lymphoma 8 years prior.
This case was reviewed at a multidisciplinary tumor
board to determine the appropriate course of manage-
ment. She was not deemed a candidate for systemic
therapy in light of her age and functional status. She
underwent a 7-day course of high-dose prednisone (100
mg daily) before starting palliative radiation at a dose of
3600 cGy in 18 fractions. She subsequently developed
mucositis, and was treated palliatively for symptom
control. She had recurrent aspiration and developed
bacteremia secondary to aspiration pneumonia for which
she opted to forgo antibiotics. She died approximately 3
months following her initial presentation, before a repeat
laryngeal examination could be conducted.
Discussion
Squamous cell carcinoma is the most frequently encoun-
tered cancer of the larynx; less commonly encountered
laryngeal cancers include adenocarcinoma, adenoid cys-
tic carcinoma, and neuroendocrine tumors. Malignant
lymphomas account for less than 1% of all laryngeal
tumors [8]. While the head and neck is the second most
common extranodal site of involvement in non-Hodgkin
lymphoma (NHL), the larynx is rarely involved, with
structures typically affected being Waldeyer’s ring, ocular
adnexal structures, the nasal cavity, nasopharynx,
paranasal sinuses, thyroid gland, as well as salivary
glands [9, 10]. Among cases of NHL affecting the larynx,
the most common classifications described in the litera-
ture include mucosa-associated lymphoid tissue (MALT)
lymphoma, plasmacytoma, and diffuse large B cell lymph-
oma. The supraglottic larynx is most commonly involved
[9]. Among extranodal head and neck presentations of
sporadic Burkitt lymphoma, the nasopharynx and tonsils
were the most common sites of occurrence in one large
Fig. 2 Supraglottic larynx biopsy demonstrating infiltrating sheets of poorly differentiated lymphoid cells, numerous mitoses, and tingible body
macrophages imparting a “starry-sky” pattern. a Hematoxylin and eosin (H&E) stain 40× magnification. b H&E stain, 100× magnification. c Tumor
cell CD20 reactivity, 100× magnification. d Tumor cell c-myc reactivity, 100× magnification. e Tumor cell Ki-67 reactivity
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case series of American sporadic Burkitt lymphoma [3].
Other extranodal sites of involvement within the head and
neck, which occur in less than 5% of patients with
sporadic Burkitt lymphoma, include the nasopharynx,
tonsils, palate, sinuses, nasal septum, and other facial
bones [3, 6, 11, 12]. This is the first reported case of
primary Burkitt lymphoma of the larynx.
The aggressiveness of primary treatment for Hodgkin
lymphoma, especially radiation therapy, is a primary risk
factor in the development of subsequent lymphoma [13].
Our patient’s development of non-Hodgkin, Burkitt-type
lymphoma following recent irradiation for cervical
Hodgkin lymphoma is also an exceedingly uncommon
occurrence. NHL is reported to occur following treat-
ment for Hodgkin lymphoma at a rate of only 0.9% at
6.7 years, and 1.6% at 15 years [14].
To ascertain the frequency of radiation-induced Burkitt
lymphoma, we performed a detailed electronic search of
PubMed, MEDLINE, and Embase for studies reporting on
radiation-induced Burkitt lymphoma. The following
MeSH terms were used in varying combinations: Burkitt
lymphoma, radiation-induced, radiotherapy, radiation-in-
jury, and neoplasm. The search identified 22 potential
studies, of which one was relevant for the qualitative
synthesis [15]. We subsequently performed a hand-search
of the literature which yielded one additional study for in-
clusion in our analysis [7]. These two studies together
identified a total of 18 cases of Burkitt lymphoma which
developed following prior radiation treatment for primary
malignant neoplasm (Table 1). One case occurred in the
mandible of a patient previously treated for oropharyngeal
cancer [15]. This is, to the best of our knowledge, the only
previously described case of Burkitt lymphoma developing
in the head and neck secondary to prior radiation
treatment.
The diagnosis of Burkitt lymphoma is made on the
basis of histology and immunohistochemistry. On histo-
logic examination, it is characterized by neoplastic
lymphoid cells with round nuclei, dispersed chromatin,
several small nucleoli, and a small amount of amphophi-
lic cytoplasm. Mitoses are numerous and the tumor cells
are admixed with tingible body macrophages, which are
macrophages phagocytosing apoptotic debris, imparting
a “starry sky” pattern. Most Burkitt lymphomas are
immunoreactive for surface immunoglobulin M (IgM),
as well as pan-B cell antigens including CD19, CD20,
and CD22, and co-express CD10, CD43, and BCL6, but
not CD5, CD23, BCL2, or TdT [16, 17] Nuclear staining
with c-myc antibody is positive: in all cases of Burkitt
lymphoma, a translocation exists between the c-Myc
gene and either the IgH gene, as is found in 80% of
cases, or either the kappa or lambda light chain gene,
found in the other 20% [18]. Another important feature
of Burkitt lymphoma is that nearly 100% of the tumor
Table 1 Reported cases of Burkitt lymphoma occurring following prior radiation treatment for primary malignant neoplasm
Case Patient agea/sex Primary neoplasm Treatment of primary neoplasm Time from primary neoplasm
to Burkitt lymphoma
1 13/M Hodgkin’s lymphoma Chemo + RT 132 months
2 21/F Hodgkin’s lymphoma Chemo + RT 90 months
3 45/M Hodgkin’s lymphoma Chemo + RT 84 months
4 34/M Hodgkin’s lymphoma Chemo + RT 36 months
5 19/F Hodgkin’s lymphoma Chemo + RT 168 months
6 39/M Hodgkin’s lymphoma Chemo + RT 78 months
7 67/M Hodgkin’s lymphoma Chemo + RT 28 months
8 32/M Hodgkin’s lymphoma Chemo + RT 97 months
9 38/M Hodgkin’s lymphoma Chemo + RT 120 months
10 20/M Hodgkin’s lymphoma Chemo + RT 100 months
11 25/M Hodgkin’s lymphoma Chemo + RT 99 months
12 36/M Hodgkin’s lymphoma Chemo + RT 65 months
13 44/F Hodgkin’s lymphoma Chemo + RT 102 months
14 33/M Hodgkin’s lymphoma Chemo + RT 112 months
15 21/M Hodgkin’s lymphoma RT 72 months
16 39/F Hodgkin’s lymphoma Chemo + RT 88 months
17 13/F Rhabdomyosarcoma Chemo + RT 6 years
18 71/M Oropharyngeal CA RT 15 years
Cases 1–16 from Salloum et al., 1996 [7]; cases 17 and 18 from Nagasaki et al., 2009 [15]
CA cancer, Chemo chemotherapy, F female, M male, RT radiotherapy
aPatient age at time of diagnosis of Burkitt lymphoma
Quimby et al. Journal of Medical Case Reports  (2017) 11:65 Page 4 of 6
cells are positive for Ki-67, a proliferation index marker,
in keeping with the tumor’s extremely rapid rate of
growth: the doubling time of Burkitt lymphoma is
among the fastest of any human malignancy [19]. Of
note, EBV antibody titers are found to be positive in al-
most 100% of patients with endemic Burkitt lymphoma,
but are only positive in 15 to 30% of patients with spor-
adic Burkitt lymphoma [16].
Given its fast-growing nature, prompt diagnosis of
Burkitt lymphoma is essential to prevent local growth
with compression of vital structures in the head and
neck, or early widespread dissemination. The former
occurred in the case we described, resulting in airway
obstruction. Typical staging consists of abdominal and
chest CT, a bone marrow biopsy, and cerebrospinal fluid
(CSF) testing. Due to our patient’s advanced age, poor
functional status, and palliative treatment approach, a
staging workup was not performed. Although localized
early stage Burkitt lymphoma is highly responsive to
chemotherapy, advanced age and high tumor burden at
presentation are poor prognostic factors [16, 20].
The treatment of Burkitt lymphoma typically consists of
intermittent high-dose chemotherapy, most commonly
using cyclophosphamide, vincristine, doxorubicin, and
methotrexate. Rituximab, a monoclonal CD20 antibody,
has also shown some promise when used in conjunction
with a typical chemotherapeutic regimen [21]. Tumor
debulking may be beneficial as an adjunct therapy when
the anatomical location is permissive, although its role in
the treatment of head and neck presentations of Burkitt
has not been well studied [22, 23]. When prognosis is
poor, as in the case described, locoregional radiation plays
a palliative role in providing local symptom control [24].
Conclusions
Burkitt lymphoma is a B cell NHL with an extremely fast
rate of growth, necessitating prompt diagnosis. Sporadic
Burkitt lymphoma occasionally presents extranodally in
the head and neck, although the most common head
and neck presentation is cervical adenopathy. Rarely,
radiation therapy has been linked to the subsequent
development of Burkitt lymphoma. This case report
describes a rare presentation of Burkitt lymphoma of the
larynx in a 90-year-old patient previously irradiated for
Hodgkin lymphoma. It represents the first reported case
of Burkitt lymphoma in the larynx, and only the second
described case of irradiation-induced Burkitt lymphoma
occurring in the head and neck. It highlights the need to
maintain a broad differential in the assessment of malig-
nancies of the larynx, particularly in the context of a
prior history of radiation treatment. Biopsy is a neces-
sary step in the diagnosis of Burkitt lymphoma and in
subsequent treatment planning, including selection of an
appropriate chemotherapeutic regimen. When detected
early, Burkitt lymphoma has a favorable prognosis and
high remission rates. However, high tumor burden, ad-
vanced age, and poor functional status are associated
with disease progression. In advanced stage or chemore-
sistant disease, there is good evidence that radiotherapy
provides local symptom control.
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